Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549)

Category Primary study
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: cfb1d70a2367ba8e1a861de1018154a9beebe6a6
First added on: Feb 14, 2025